Business Wire

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-Free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

19.5.2020 15:00:00 EEST | Business Wire | Press release

Share

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), today announced publication of positive two-year data from the ALPS Registry of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System. Results were published online yesterday in the Journal of Endovascular Therapy and will also appear in the August print issue of the journal. The ALPS Registry is the largest study to date of No-Option CLTI patients treated with the LimFlow System reporting mid- and long-term results.

“In this complex group of patients, pDVA using the LimFlow device has shown to be feasible and safe with high technical success and good amputation-free survival at six months up to 24 months coupled with good wound healing,” said the paper’s lead author, Andrej Schmidt, MD, Head of the Angiology CathLab at Leipzig University Hospital, Germany. “In selected patients with No-Option CLTI, pDVA is a safe and effective treatment to prevent amputation and heal wounds.”

“Patients with this disease suffer with chronic ulcers, often including gangrene, recurrent pain, and a very poor quality of life. CLTI is associated with poor mid- and long-term survival, and no-option patients often face the worst outcomes,” said Roberto Ferraresi, MD, Chief of the Peripheral Interventional Unit at the San Carlo Clinic, Milan, Italy, co-author of the paper, and a pioneer in the interventional treatment of CLTI. “These patients desperately need an option to avoid amputation and improve their life, and LimFlow offers a very promising alternative for them.”

The ALPS Registry is a multi-center, retrospective study conducted at centers in Alkmaar, Netherlands; Leipzig, Germany; Paris; and Singapore encompassing 32 end-stage – or “no-option” – CLTI patients. All patients had non-healing wounds on the target foot and no arterial target for surgical or endovascular revascularization. Among them, 66 percent had diabetes, 53 percent had renal insufficiency, and 16 percent were dialysis dependent. The majority of patients had experienced failed prior attempts at revascularization.

The registry reported major amputation-free survival of 84 percent, 71 percent, and 67 percent, respectively, at six months, one year and two years. Additionally, a positive trend of successful wound healing was demonstrated, with 73 percent of wounds completely healed at two years. Technical success was 97 percent.

When all other therapeutic options have been exhausted and a CLTI patient is facing major amputation, the minimally-invasive LimFlow system is designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the veins. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves quality of life, enables wound healing and prevents major amputation.

“It is very gratifying to see these durable results being demonstrated by the LimFlow System in a real-world setting with consecutive patients,” said LimFlow CEO Dan Rose. “For these no-option patients, the next intervention for their leg was going to be major amputation, with the associated morbidity and high mortality risk that comes with amputation. Instead, two years later, the vast majority of patients are alive, with almost three-quarters of them experiencing completely healed wounds. This registry adds to the building clinical evidence that LimFlow therapy is an effective solution for no-option patients.”

CLTI is the most severe form of PAD and often occurs in patients suffering from coronary artery disease, diabetes, and chronic kidney disease. Patients with CLTI often experience profound, chronic pain and develop festering wounds or infections that lead to major limb amputation, an event closely associated with increased mortality and reduced quality of life. To relieve the symptoms of CLTI, patients today are treated primarily with angioplasty or open bypass surgery. In many late-stage patients, however, neither option is feasible due to extensive disease in the target arteries or other anatomical constraints.

Click here to view a video of how the LimFlow System works.

About LimFlow SA

LimFlow is a private, venture-backed medical device company transforming the treatment of chronic limb-threatening ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease, kidney disease and an aging population. For more information, visit www.limflow.com.

CAUTION: The LimFlow technology is approved for investigational use only in the United States. The LimFlow System received the CE Mark in October 2016. The LimFlow System has not been approved for sale in the USA, Canada, or Japan.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com, +1 310-902-1274

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CORRECTING and REPLACING Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally19.11.2026 23:11:00 EET | Press release

This announcement replaces the release dated November 17, 2026 with the following version: J.P. Morgan Payments was added to the subhead and after the 11th paragraph. Multimedia was also updated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ Visa Agentic Ready Acceptance Partners The updated release reads: VISA EXPANDS AGENTIC READY TO HELP SCALE TRUSTED AI COMMERCE GLOBALLY Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, J.P. Morgan Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem. Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commer

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release

When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release

North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 16:32:00 EET | Press release

Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue ch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye